7 most recent filings and news items mentioning SBEV. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/SBEV/news?limit=20"
Pull SBEV filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/daySplash Beverage Group partners with Lupvindol Biosciences to advance CannEpil for companion-animal oncology and pain through FDA veterinary pathways, retaining ownership of resulting data and IP.
View filing at SEC.gov →Splash Beverage Group and Argent Biopharma amended their agreement to expand the field to veterinary purposes and set different royalty rates of 15% for human and 10% for veterinary sales. This strategic move positions the company for potential new market segments in the healthca
View filing at SEC.gov →The company settled approximately $3.3 million in legacy liabilities and approved a 1-for-4 reverse stock split. This move is intended to bolster balance sheet strength and ensure continued compliance with NYSE American listing requirements.
View filing at SEC.gov →Splash Beverage Group received approval from NYSE American to regain compliance through January 2027, avoiding a potential delisting. This continued listing status allows the company to execute its strategic transformation into a cannabinoid wellness platform while meeting exchan
View filing at SEC.gov →Splash Beverage Group entered a global licensing deal for the epilepsy drug CannEpil and received $1 million in funding. This acquisition targets patients with drug-resistant epilepsy and leverages existing international commercialization pathways for U.S. development.
View filing at SEC.gov →Splash Beverage Group completed a strategic investment in Avicanna Inc., a commercial-stage cannabinoid-based biopharmaceutical company, as part of its transformation into a cannabinoid healthcare platform. The investment signals Splash's strategic pivot toward regulated medical
View filing at SEC.gov →Splash Beverage submitted a compliance plan to NYSE American on May 28, 2026 to address stockholders' equity concerns, with potential cure period through January 29, 2027. The company's non-binding letter of intent with Medterra CBD expired on May 4, 2026, but management continue
View filing at SEC.gov →